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Goal:
The goal of this activity is to increase the
awareness of the pharmacist on the
complications surrounding hypertension
management in the elderly individual,
clarify the differences in current guideline
recommendations, and aid in making the
most appropriate drug therapy decisions
regarding the management of hypertension.
Objectives
1. Identify the differences and similarities in
clinical practice guideline recommendations
for management of hypertension in the
elderly patient.
2. List changes in the physiology of elderly
individuals that create more complicated
management scenarios
3. Discuss potential adverse drug effects
that may be experienced by an elderly
individual when prescribed antihypertensive medications
4. Select an appropriate drug therapy
regimen and treatment goals for an elderly
patient with uncontrolled hypertension
Introduction:
Hypertension affects 70.8% of individuals
over the age of 65, making this population
the most likely to experience complications
of uncontrolled hypertension such as organ
damage and cardiovascular disease.1
However, data to support the target blood
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pressure goal of <140/80 mm Hg in the
elderly population as suggested in previous
guidelines has not been robust. Further
complicating matters, most trials evaluating
hypertensive goals and pharmacological
management in recent years only included
individuals <80 years of age. When pooling
results of studies including individuals
between 80 and 90 years of age, treated
patients showed a reduction in both stroke
and cardiovascular morbidity, but also a
significant increase in all-cause mortality
compared to controls. As a result, many
practitioners are without clear direction
when treating elderly patients.2, 3 Built upon
the results of these trials that included the
elderly population, the 2014 Evidence Based
Guideline for the Management of High
Blood Pressure in Adults (JNC8), along with
the Clinical Practice Guidelines for the
Management of Hypertension in the
Community also released in 2014 by the
American Society of Hypertension and
International Society of Hypertension
(ASH/ISH) have resulted in a new approach
to managing hypertension in the aging
population.
Pathophysiology
Hypertension is seen with increased
frequency in the elderly population due to
age-associated changes in vasculature
complicated by lifestyle changes,
comorbidities, and use of certain
medications (Table 1). In the aging
individual, large vessels become less
distensible, endothelial dysfunction occurs,
forward flow is reduced, and coronary
stenosis is enhanced. Glomerulosclerosis
and interstitial fibrosis then results in
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progressive renal dysfunction and causes
increased intracellular sodium, reduced
sodium-calcium exchange, and volume
expansion which further contributes to the
patient’s hypertension due to increased
sodium sensitivity.2 These pathological
changes in the elderly paired with a more
sedentary lifestyle and medication use cause
an elevation in systolic blood pressure (SBP)
to become more likely. Untreated
hypertension in the elderly is the first step in
a cascade of events that may result in
additional comorbidities. Poor blood
pressure control in this population can result
in cerebrovascular disease; coronary artery
disease (CAD); disorders of the left
ventricular structure and function; rhythm
disorders; aortic and peripheral arterial
disease; chronic kidney disease (CKD),
ophthalmic disorders; and decreased quality
of life.2
Patients of African descent pose different
challenges in the management of
hypertension. This population is more
sensitive to the blood pressure raising effects
of sodium than other groups, potentially
explaining why these individuals tend to
experience hypertension earlier in life and
have more severe hypertension than other
ethnicities. African Americans are
particularly vulnerable to strokes and are 3
to 5 times more likely than Caucasians to
have renal complications or end-stage
kidney disease as a result of uncontrolled
hypertension.4, 5
Evaluating Blood Pressure Goals and
Management
Prior to the release of the JNC 8 and
ASH/ISH guideline statements, the
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American College of Cardiology Foundation
and American Heart Association’s
(ACCF/AHA) 2011 Expert Consensus
Document on Hypertension in the Elderly
was available to aid in setting blood pressure
goals in the elderly population. According
to the ACCF/AHA 2011 document, the
blood pressure goal for all individuals with
uncomplicated hypertension was <140/90
mm Hg. The expert panel noted that this
recommendation was based on opinions of
the writing panel, rather than randomized
controlled trials, and stated for individuals
80 years of age and older a SBP of 140 to
145 mm Hg would be acceptable.2
More recently, JNC 8 and ASH/ISH
guidelines have indicated new blood
pressure targets for the elderly population.
As outlined in Table 2, JNC8 utilizes the
blood pressure goal of <150/90 mmHg for
those patients 60 years of age and older;
while ASH/ISH imposes this same target for
patients 80 years of age and older.4, 5
When initiating antihypertensive
medications in the elderly, the ACCF/AHA
2011 Expert Panel recommends starting at
the lowest possible dose and gradually
increasing, depending on response, to the
maximum tolerated dose. A second
medication is then added if the patient has
not reached their blood pressure goal.2, 4, 5
On the other hand, the strategies proposed
by JNC8 and ASH/ISH indicate some
patients may need multiple pharmacologic
agents at time of diagnosis to achieve their
goals when >20/10 mmHg above the desired
blood pressure.4, 5
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Why a Difference?
The reason for differences between the
various guidelines lies in the evidence upon
which each document was built. As
mentioned previously, the blood pressure
goal set by the ACCF/AHA 2011 document
was set by opinions of the expert panel.2
ASH/ISH was similar in that the blood
pressure goals were also set based on
opinions of the expert writing panel, while
JNC8 was different in that blood pressure
goals were formulated based on reviews of
randomized controlled trials.4,5 As dictated
in the statement of purpose for the ASH/ISH
guidelines, the authors were focused on
practical applicability in the clinical setting.
This panel further relied upon the evidence
for a defined goal blood pressure of <140/90
mm Hg from trials such as ACCOMPLISH,
ALLHAT, and VALUE that included
individuals over the age of 60 and the SBP
goal of <150 mm Hg from the HYVET trial
for individuals >80 years of age.5-10 On the
other hand, JNC8 chose to utilize evidencebased criteria using trials that evaluated
individuals over the age of 60 such as
SHEP, Syst-EUR, and others.11-14 Table 3
outlines the studies that supported each
guideline’s recommendations.
Drug Therapy
The majority of elderly individuals
presenting with uncontrolled hypertension
will have an additional comorbidity
indicating the need for a specific
antihypertensive medication or drug class.
Table 4 compares recommended initial drug
therapy options amongst the guidelines
previously discussed. It is important to note
initial drug therapy is based on race, not age;
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however, when selecting appropriate therapy
for elderly individuals the adverse effects of
each medication (Table 5) must be
considered as this population is more prone
to dehydration, hypotension, and
bradycardia due to changes in physiology.2
While the JNC8 and ASH/ISH guidelines
are more flexible in initial drug therapy
choice, the ACCF/AHA 2011 expert
consensus panel recommends a thiazide
diuretic as the initial drug of choice.2
Thiazide diuretics have been associated with
reduced cardiovascular, cerebrovascular,
and renal adverse outcomes in trials, but
may exacerbate age-related physiological
changes such as contracted intravascular
volumes, orthostatic hypotension due to
sodium and water depletion, exacerbation of
gout, and an increased risk of arrhythmias
due to electrolyte depletion.2,6,12,13
Dihydropyridine (DHP) calcium channel
blockers have been supported by positive
evidence in controlled trials for the elderly
population.8, 9 Since an elderly individual’s
hypertension is characterized by arterial
stiffness, decreased vascular compliance,
and diastolic dysfunction, the drug’s ability
to promote vasodilator activity make these
drugs appealing. It is important to note that
similar effects are not seen with non-DHP
calcium channel blockers such as verapamil
and diltiazem and, when selected for
therapy, these agents require close
monitoring for bradycardia in this
population.
Other agents that may be appropriate to
initiate in an elderly patient based on
comorbidities require additional monitoring
to ensure safety in this sensitive population.
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Angiotensin converting enzyme (ACE)
inhibitors and angiotensin II receptor
blockers (ARBs) must be accompanied by
diligent monitoring of renal function and
serum potassium levels but are often times
used for their renal protective properties in
patients with kidney disease or diabetes
mellitus. Beta blockers lack evidence for
use as a primary antihypertensive agent in
the elderly population, except in patients
with an existing comorbidity noted in Table
5. When these agents are selected,
practitioners should be aware these drugs
mask the signs of hypoglycemia in diabetic
patients and non-selective agents may
exacerbate pulmonary diseases. Loop
diuretics can be used as adjuvant therapy in
the elderly with hypertension complicated
by heart failure or chronic kidney disease;
however, caution and close monitoring
should be utilized due to these agents’ large
adverse effect profile including increased
glucose, electrolyte disturbances, and
dehydration. Finally, mineralocorticoid
antagonists and epithelial sodium transport
channel antagonists may be useful in
combination with other agents for patients
with refractory hypertension or an additional
indication such as heart failure; however,
close monitoring of serum potassium is
important.
Some antihypertensive agents, on the other
hand, should be avoided in the elderly
population and are listed on the Beers
criteria and STOPP/START criteria.15, 16
Both tools outline potentially inappropriate
medications for older patients based on the
medication’s potential side effects and/or the
changing physiology of the elderly
individual’s body. For example, alpha
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blockers and non-specific vasodilators, such
as hydralazine and minoxidil, are
recommended as last line agents due to the
ability of these medications to increase fall
risk secondary to the orthostatic hypotension
these agents cause. Additionally, alpha
blockers should be avoided due to the
proven excessive cardiovascular events seen
in the ALLHAT trial.7 Alpha-agonists, such
as clonidine, also meet Beers criteria for
their ability to produce central nervous
system adverse effects.
Conclusion
Uncontrolled hypertension is an ubiquitous
disease state in the elderly population;
however, given the age-related changes in
physiology, management of these
individuals can be complicated. Patients
should be evaluated on an individual basis
for tolerability of a lower blood pressure to
determine how restrictive their blood
pressure goal may be, utilizing JNC8 or
ASH/ISH guidelines in combination with
the ACCF/AHA 2011 expert consensus
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guidelines. Practitioners must also take
comorbidities, drug burden, and potential for
adverse effects into consideration when
choosing an antihypertensive therapy
appropriate for their elderly patient.

The Pharmacists Education
Foundation (PEF) is accredited by
the Accreditation Council for Pharmacy
Education (ACPE) as a provider of
continuing pharmacy education. To receive
continuing pharmacy education (CPE)
pharmacists MUST COMPELTE THE
ONLINE QUIZ AND EVALUATION
FORM. A score of 70% or above is required
to receive CPE credit. The link to the quiz
can be accessed from the home study section
in the CE Portal of the IPA website,
www.indianapharmacists.org. This is a free
service of IPA members in 2015. Initial
release date: 10/30/2015. Expiration Date:
10/30/2018. Questions: Call IPA office at
317-634-4968.
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TABLE 1
Factors That Worsen Hypertension in the Elderly2
Lifestyle Changes
 Smoking and alcohol use
 Limited physical activity
 Altered or reduced
appetite
 Excessive sodium intake

Comorbidities
 Renal artery stenosis

Medications
 Nonsteroidal anti-inflammatory
drugs (NSAIDs)

 Obstructive sleep apnea  Glucocorticoids
 Primary aldosteronism

 Sex hormones

 Thyroid disorders

 Antirheumatic agents (e.g.
cyclosporine, leflunomide)
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TABLE 2
Blood Pressure Goals 2, 4, 5
Uncomplicated Hypertension
ACCF/AHA All patients: <140/90 mm Hg
2011

DM

CKD

<130/80 mm Hg <130/80 mm Hg

>80 years of age: 140 to 145 mm Hg
systolic can be acceptable

JNC8

< 60 years of age: <140/90 mm Hg

<140/90 mm Hg <140/90 mm Hg

> 60 years of age: <150/90 mm Hg
ASH/ISH

<80 years of age: <140/90 mm Hg
>80 years of age: <150/90 mm Hg

CKD: chronic kidney disease, DM: diabetes mellitus

<140/90 mm Hg <140/90 mm Hg
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TABLE 3
Hypertension Trials

Trial
ACCOMPLISH8

Study
Participants
N= 11,506

Pharmacologic
Intervention
(Benazepril +

Mean Age:

amlodipine) vs.

<130/80 mmHg in participants

68

(benazepril +

with history of DM

HCTZ)

Important Considerations and
Results
 Goal BP: <140/90 mm Hg,



ACEI/ CCB combination is
superior to ACEI/ HCTZ in
reduction in morbidity and
mortality



40% of participants were 70
years of age or older



No difference in morbidity
and mortality in those >80
years of age

ALLHAT7

N=33,357

Amlodipine,



Goal BP: <140/90 mmHg

Mean Age:

lisinopril or



25% increase in CV events in

67

doxazozin vs.

doxazosin arm including a

chlorthalidone

204% increase in HF and 19%
increase in stroke
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57% of participants were 65
years of age or older

HYVET6

N=3,845

Indapamide +/-



Goal BP: <150/80 mmHg

Mean Age:

perindopril



All patients were 80 years of

84

age or older


Reduction of stroke, HF, and
CV events in the indapamide
arm



Significant reduction in allcause death

INVEST10

N=22,576

Verapamil vs.

Mean Age:

atenolol



Goal BP: <140/90 mmHg,
<130/85 mmHg in participants

66

with history of DM


33% of participants were 70
years of age or older



No difference in outcomes in
those >80 years of age

SHEP13

N=4,736
Mean Age:
72

Chlorthalidone



Goal SBP: <150 mmHg



Reduced incidence of stroke in
all patients in treatment arm
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Syst-EUR14

N=4,695

Nitrendipine

Mean Age:
70



Goal SBP: <150 mmHg



Treatment to goal BP
improves CV and
cerebrovascular outcomes and
lowers mortality

ACE: angiotensin converting enzyme; BP: blood pressure; CCB: calcium channel blocker; CV:
cardiovascular; HCTZ: hydrochlorothiazide; HF: heart failure; SBP: systolic blood pressure
TABLE 4
Initial Treatment Options for Uncomplicated Hypertension 2, 4, 5
Non-African American Individuals
ACCF/AHA 2011

Thiazide-type diuretic

African American
Individuals
Thiazide-type diuretic

JNC8

ACE inhibitor

CCB

ARB

Thiazide-type diuretic

CCB
Thiazide-type diuretic
ASH/ISH

<60 years of age

>60 years of age

CCB

ACE inhibitor

CCB

Thiazide-type diuretic

ARB

Thiazide-type
diuretic

ACE: angiotensin converting enzyme, ARB: angiotensin II receptor blocker, CCB: calcium
channel blocker
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TABLE 5
Drug Therapy Options for the Elderly 2, 5

Drug Class
Thiazide diuretics

Important Considerations


Promotes orthostatic hypotension,

Monitoring


depletion of electrolytes,

Sodium, potassium,
magnesium

hyperuricemia, glucose intolerance



Volume status

and dyslipidemia



Blood glucose



Fasting lipid panel



Uric acid level



CrCl: not effective in
patients with CrCl
<30 ml/min

Calcium channel



blockers



Associated with postural



Bradycardia (most

hypotension with an increased risk

common with DHP

of dizziness and falls

CCB)

Verapamil and diltiazem may



Ankle edema

precipitate heart block in those with



Headache

underlying defects
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ACE inhibitors





Avoid verapamil, diltiazem, and



Constipation (most

nifedipine in those with preserved

common with

ejection fraction heart failure

verapamil)

May cause chronic dry cough,



Angioedema (more

angioedema, hyperkalemia, and

common in African

renal failure

American patients)

More effective in reducing BP in



Potassium

white patients than African



Renal function; may

Americans

increase SCr up to
30%


May need to start at
lower initial dose for
CrCl<30 ml/min

ARBs





May cause chronic dry cough,



Angioedema (less

angioedema, hyperkalemia, and

common than ACE

renal failure

inhibitors)

More effective in reducing BP in



Potassium

white patients than African



Renal function; may

Americans

increase SCr up to
30%
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Direct renin



inhibitors
Beta blockers



Alpha-beta
blockers



May cause hypotension,



Potassium

hyperkalemia, and renal failure



Renal function

Useful in elderly patients who have



Bradycardia

CAD, HF, certain arrhythmias,



Depression

migraine headaches, or tremor



Sexual dysfunction

May mask signs of hypoglycemia



Fasting lipid panel



Potassium,

in patients with DM
Loop diuretics



Useful in patients with volume
overload (ie. HF and CKD)



Mineralocorticoid



antagonists


magnesium

May cause electrolyte disturbances



Volume status

and glucose intolerance



Fasting lipid panel



Blood glucose



Uric acid level



Gynecomastia and

Does not cause metabolic
disturbances

sexual dysfunction in

May cause hyperkalemia; avoid in

men treated with

combination with ACE inhibitors

spironolactone

and ARBs



Potassium



Dose adjusted with
CrCl <50 ml/min, not
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recommended <30
ml/min
Epithelial sodium



transport channel


Does not cause metabolic



Potassium

disturbances



Use not

Minimal effect on BP; used mostly

recommended with

(amiloride and

for potassium sparing effect in

CrCl <50 ml/min

triamterene)

combination with diuretics

antagonists

ACE: angiotensin converting enzyme, ARB: angiotensin II receptor blocker, BP: blood pressure,
CAD: coronary artery disease, CCB: calcium channel blockers; CKD: chronic kidney disease ,
CrCl: creatinine clearance, DHP: dihydropyridine, DM: diabetes mellitus, HF: heart failure,
SCr: serum creatinine

